Reviewer's report

Title: Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

Version: 2 Date: 27 March 2012

Reviewer: Andrea Sartore Bianchi

Reviewer's report:

Authors chose for this retrospective analysis a setting that is not appropriate to their aim; there are no revisions to address by my side in the revised manuscript.

Level of interest: An article of insufficient interest to warrant publication in a scientific/medical journal

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I received reimbursements and lecture fees from Amgen, Merck-Serono and Roche.